Japanese hospital to test new cancer therapy

Afp
Saturday 22 January 2011 01:00
Comments

Medical researchers in Japan say they will start the world's first clinical studies of a radiation therapy using accelerator-based neutron beams to kill cancer cells.

The National Cancer Centre in Tokyo and a Japanese medical equipment maker - Cancer Intelligence Care Systems - plan to start the studies using "boron neutron capture therapy (BNCT)" in three years, the centre said.

The BNCT is an innovative radiation treatment which kills cancer cells selectively without side-effects, but it requires a massive facility including a nuclear reactor to produce neutron beams.

By using a particle accelerator, which is cheaper, safer and smaller than a reactor, it will become feasible for a hospital to provide the therapy on actual patients, the centre told journalists Tuesday.

The centre hopes to try the special radiation therapy on patients with cancers that have been difficult to treat in conventional procedures, such as brain tumors and melanoma, it said.

oh/bsk

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in